Cardiovascular Systems, Inc. (NASDAQ:CSII) has received a consensus recommendation of “Buy” from the nine research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $34.40.
Several analysts have commented on the company. Needham & Company LLC restated a “buy” rating and issued a $37.00 price target (up previously from $32.00) on shares of Cardiovascular Systems in a report on Friday. BidaskClub cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Thursday. Bank of America Corporation cut Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a report on Wednesday, June 21st. Finally, TheStreet upgraded Cardiovascular Systems from a “d” rating to a “c-” rating in a report on Thursday, May 4th.
A number of hedge funds have recently bought and sold shares of the stock. Winslow Evans & Crocker Inc. boosted its stake in Cardiovascular Systems by 21.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 6,550 shares of the medical device company’s stock valued at $210,000 after buying an additional 1,150 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Cardiovascular Systems during the second quarter worth about $319,000. Nuveen Asset Management LLC purchased a new stake in shares of Cardiovascular Systems during the first quarter worth about $1,406,000. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Cardiovascular Systems by 21.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 31,658 shares of the medical device company’s stock worth $895,000 after buying an additional 5,612 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Cardiovascular Systems by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 157,394 shares of the medical device company’s stock worth $4,450,000 after buying an additional 13,654 shares during the last quarter. Institutional investors own 75.83% of the company’s stock.
Cardiovascular Systems (NASDAQ:CSII) traded down 0.12% on Friday, reaching $32.40. 120,434 shares of the company’s stock were exchanged. Cardiovascular Systems has a 1-year low of $18.67 and a 1-year high of $33.11. The company’s market capitalization is $1.06 billion. The company has a 50 day moving average price of $31.22 and a 200-day moving average price of $28.18.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Wednesday, May 3rd. The medical device company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $52.10 million during the quarter, compared to analysts’ expectations of $51.13 million. Cardiovascular Systems had a negative return on equity of 4.36% and a negative net margin of 3.72%. The firm’s quarterly revenue was up 17.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.31) EPS. On average, equities research analysts anticipate that Cardiovascular Systems will post ($0.13) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/07/18/cardiovascular-systems-inc-nasdaqcsii-receives-34-40-consensus-pt-from-analysts.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.